Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
BUSINESS
Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
Sumitomo Dainippon Pharma has grabbed development and commercialization rights in 13 Asian markets including Japan for imeglimin, an investigational type 2 diabetes drug being developed by France’s Poxel, the two companies said on October 30. According to the pair, imeglimin…
To read the full story
Related Article
- Sumitomo Dainippon Files Japan NDA for Poxel’s Diabetes Med
July 31, 2020
- Sumitomo/Poxel Wraps Up Japan Pivotal Program for Imeglimin with Successful Long-Term Study
December 23, 2019
- Poxel/Sumitomo’s Imeglimin Delivers Again, This Time in Insulin Combo Study
June 26, 2019
- Diabetes Drug Imeglimin Hits Primary Goal in Japan PIII: Sumitomo, Poxel
April 10, 2019
- Patient Enrollment Completed in Japan PIII Study of Diabetes Treatment Imeglimin: Poxel
October 10, 2018
- Poxel Forms Japan Outpost, Hitches Janssen’s Kaneko as Country Chief
September 14, 2018
- Poxel Eyeing Japan as 1st Market for Its Lead Diabetes Candidate: CEO
February 6, 2018
- Sumitomo Dainippon Begins Japan PIII for Poxel’s Diabetes Med
December 28, 2017
- Sumitomo Dainippon Beats 1st Half Guidance, Ups Full-Year Outlook
October 31, 2017
BUSINESS
- Takeda Returns to Core Profit Growth, CEO Confident in Trajectory
October 30, 2026
- Novartis Japan President Pullicino to Step Down for Global Role
October 30, 2026
- Lilly’s Imulrio Reaches Japan Market 10 Months after Approval
October 30, 2026
- Ono’s First-Half Operating Profit Up 11% Despite Forxiga Sales Hit
October 30, 2026
- Shionogi Logs Record H1 Revenue as Acquisitions Pay Off
October 30, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…